Trial Profile
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms REFLECT
- Sponsors Eisai Co Ltd
- 06 Jun 2023 Results of post hoc analysis (n=1189) of patients with nonviral etiology from REFLECT presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 20 Sep 2022 Results of sub-analysis assessing objective response as an independent predictor of overall survival in individuals with unresectable hepatocellular carcinoma receiving systemic anti-angiogenic therapy, published in the Journal of Hepatology.
- 07 Jun 2022 Results assessing the tumor responses in patients with unresectable hepatocellular carcinoma who were treated with lenvatinib, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.